Profund Advisors LLC Has $700,000 Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Profund Advisors LLC trimmed its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 44.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 62,291 shares of the biopharmaceutical company’s stock after selling 50,842 shares during the period. Profund Advisors LLC’s holdings in Dynavax Technologies were worth $700,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Congress Asset Management Co. MA lifted its holdings in shares of Dynavax Technologies by 0.4% during the 4th quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company’s stock worth $3,175,000 after acquiring an additional 799 shares during the period. Diversified Trust Co lifted its stake in Dynavax Technologies by 3.2% during the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 925 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,172 shares in the last quarter. SummerHaven Investment Management LLC increased its stake in shares of Dynavax Technologies by 2.4% in the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,303 shares during the last quarter. Finally, Texas Permanent School Fund Corp raised its holdings in shares of Dynavax Technologies by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 1,467 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DVAX. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Price Performance

Shares of DVAX opened at $10.87 on Wednesday. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. The stock has a market cap of $1.42 billion, a PE ratio of 181.17 and a beta of 1.37. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $15.15. The business has a 50-day simple moving average of $11.06 and a two-hundred day simple moving average of $11.44.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. During the same quarter last year, the business earned $0.03 EPS. Analysts anticipate that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.